<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on April 6, 2021</div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Washington, D.C.
      20549</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM S-8</div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-weight: bold;">UNDER THE</div>
    <div style="text-align: center; font-weight: bold;">SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">GAIN
      THERAPEUTICS, INC.</div>
    <div style="text-align: center;">(Exact name of registrant as specified in charter)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z80518b7aae814380a726f26f5b349fc4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Delaware</div>
            <div style="text-align: center;">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-weight: bold;">85-1726310</div>
            <div style="text-align: center;">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; color: #000000; font-weight: bold;">4800 Hampden Lane, Suite 200</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Bethesda, Maryland 20814</div>
    </div>
    <div style="text-align: center; margin-left: 5.4pt;">(Address of principal executive offices)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan</div>
    <div style="text-align: center;">(Full Title of the Plan)</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Eric I. Richman</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Chief Executive Officer</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Gain Therapeutics, Inc.</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">4800 Hampden Lane, Suite 200</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Bethesda, MD 20814</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(301) 500-1556</div>
      <div style="text-align: center;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;">Copies of communications to:</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Andrea L. Nicol<font style="color: #000000;">&#225;</font>s, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Skadden, Arps, Slate, Meagher &amp; Flom LLP</div>
    <div style="text-align: center; font-weight: bold;">One Manhattan West</div>
    <div style="text-align: center; font-weight: bold;">New York, New York 10001</div>
    <div style="text-align: center; font-weight: bold;">Tel: +1 (212) 735-3000</div>
    <div style="text-align: center; font-weight: bold;">Fax: +1 (212) 735-2000</div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfa161cf2f42e451c828fc097518c7185" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15.83%; vertical-align: bottom;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 2.93%; vertical-align: bottom;">&#160;</td>
          <td style="width: 52.56%; vertical-align: bottom;">
            <div>&#9744;</div>
          </td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 19.93%; vertical-align: bottom;">
            <div>Accelerated filer</div>
          </td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2.92%; vertical-align: bottom;">
            <div>&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.83%; vertical-align: bottom;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 2.93%; vertical-align: bottom;">&#160;</td>
          <td style="width: 52.56%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 19.93%; vertical-align: bottom;">
            <div>Smaller reporting company</div>
          </td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2.92%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.83%; vertical-align: bottom;">
            <div>Emerging growth company</div>
          </td>
          <td style="width: 2.93%; vertical-align: bottom;">&#160;</td>
          <td style="width: 52.56%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2.92%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. &#9723;</div>
    <div><br>
    </div>
    <div style="font-weight: bold; text-align: center;">CALCULATION OF REGISTRATION FEE</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z54df4422b29c486aa458538cfe0254e1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 32.29%; vertical-align: bottom; border-top: #000000 4px double; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Title of securities to be registered</div>
          </td>
          <td style="width: 13.35%; vertical-align: bottom; border-top: #000000 4px double; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Amount to be </div>
            <div style="text-align: center; font-weight: bold;">registered (1)</div>
          </td>
          <td style="width: 15.57%; vertical-align: bottom; border-top: #000000 4px double; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Proposed </div>
            <div style="text-align: center; font-weight: bold;">maximum offering </div>
            <div style="text-align: center; font-weight: bold;">price per share</div>
          </td>
          <td style="width: 21.68%; vertical-align: bottom; border-top: #000000 4px double; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Proposed maximum </div>
            <div style="text-align: center; font-weight: bold;">aggregate offering price</div>
          </td>
          <td style="width: 17.12%; vertical-align: bottom; border-top: #000000 4px double; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Amount of </div>
            <div style="text-align: center; font-weight: bold;">registration fee</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32.29%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Common Stock, par value $0.0001 per share</div>
          </td>
          <td style="width: 13.35%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">1,153,827(2)</div>
          </td>
          <td style="width: 15.57%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$14.96(3)</div>
          </td>
          <td style="width: 21.68%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$17,261,251.92</div>
          </td>
          <td style="width: 17.12%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,883.20</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32.29%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Common Stock, par value $0.0001 per share</div>
          </td>
          <td style="width: 13.35%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">517,902(4)</div>
          </td>
          <td style="width: 15.57%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$3.37(5)</div>
          </td>
          <td style="width: 21.68%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,745,329.74</div>
          </td>
          <td style="width: 17.12%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$190.42</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 32.29%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">Total <br>
          </td>
          <td rowspan="1" style="width: 13.35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">1,671,729 <br>
          </td>
          <td rowspan="1" style="width: 15.57%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td rowspan="1" style="width: 21.68%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">$19,006,581.66 <br>
          </td>
          <td rowspan="1" style="width: 17.12%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">$2,073.62 <br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zebc91d90f0d443bf81e9ac7a5e949eac" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="color: #000000;">Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the &#8220;</font><font style="color: #000000;"><u>Securities Act</u></font><font style="color: #000000;">&#8221;), this Registration
                Statement shall also cover any additional shares of&#160; common stock, par value $0.0001 per share (&#8220;</font><font style="color: #000000;"><u>Common Stock</u></font><font style="color: #000000;">&#8221;) of Gain Therapeutics, Inc. (the &#8220;</font><font style="color: #000000;"><u>Company</u></font><font style="color: #000000;">&#8221;) that become issuable under the Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan (the &#8220;</font><font style="color: #000000;"><u>2020 Incentive Plan</u></font><font style="color: #000000;">&#8221;) by reason of any future stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration by the Company that increases the number of outstanding shares of Common
                Stock.</font></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z98f2448e9ed54d2a8d2fb9e5a19ee1f2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #000000;">Represents 1,153,827 shares of Common Stock reserved for issuance under the 2020 Incentive Plan.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2388f0107782475380897951db34af9c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #000000;">Estimated in accordance with Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee based on a per share price of $14.96, the average of the high and low price of the common stock on
              April 1, 2021, as reported on the NASDAQ Global Market.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b21173ad0444d7ab65ed8fba2eb3052" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #000000;">Represents 517,902 shares of Common Stock reserved for issuance upon the exercise of previously granted stock options that remain outstanding under the 2020 Incentive Plan.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z909e1f3192b74bb48b820a3d4461b7dd" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(5)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #000000;">For purposes of computing the registration fee only. Pursuant to Rule 457(h) of the Securities Act, the Proposed Maximum Offering Price Per Share is based upon the weighted-average exercise price of previously
              granted stock options that remain outstanding under the 2020 Incentive Plan.</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="font-weight: bold;">PART I</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE PROSPECTUS</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd627f321235c4faca489c19288feed81" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Plan Information*</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e4a6c919e694ec3a8ccb80ec6321d93" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Registrant Information and Employee Plan Annual Information*</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;" align="left" noshade="noshade"></div>
    <div>* <font style="color: #000000;">The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the &#8220;</font><font style="font-weight: bold; color: #000000;">Registration Statement</font><font style="color: #000000;">&#8221;) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-weight: bold; color: #000000;">Securities Act</font><font style="color: #000000;">&#8221;) and the
        introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule
        428(b)(1) under the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z68fe54b1210449ca96a7a919b91a21c1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Incorporation of Documents by Reference</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The following documents filed by the Registrant are incorporated herein by reference:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fb6057cd6d64f7bad061277e754b8f1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top;">
            <div>the Registrant&#8217;s final prospectus filed on March 22, 2021 pursuant to Rule 424(b)(4) under the Securities Act in connection with the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-253303); and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfc22ac908de24ea0be4faca9173bf9aa" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>the description of the Registrant&#8217;s Common Stock contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-40237) filed with the Commission on March 17, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01
      of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities
      offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any
      statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any
      subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part
      of this Registration Statement.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z917ee8fd007b4c80b103580e6c283ffe" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Description of Securities.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ce0cb67daa44f6ba6c67bb0cfe8f530" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Interests of Named Experts and Counsel</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaebadb950c15462f9f3ae954bf71ee04" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Indemnification of Directors and Officers</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the
      corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good
      faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payment of dividends or unlawful stock purchases or redemptions, or (iv) for any transaction from which the director derived an improper personal benefit.
      Our amended and restated certificate of incorporation contain such a provision.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys&#8217;
      fees), judgments, fines, and amounts paid in settlement in connection with specified actions, suits, or proceedings, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the corporation&#8212;a &#8220;derivative
      action&#8221;), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct
      was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys&#8217; fees) incurred in connection with defense or settlement of such action, and the statute
      requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. Our amended and restated certificate of incorporation and amended and restated bylaws contain such a
      provision.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: #000000;">We have in effect a directors and officers liability insurance policy indemnifying our directors and officers for certain liabilities incurred by them, including liabilities under the Securities Act and
      the Exchange Act. We pay the entire premium of this policy.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">We entered into indemnification agreements with each of our directors and officers that provide the maximum indemnity allowed to directors and officers by Section 145 of the Delaware General Corporation
      Law and which allow for certain additional procedural protections.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities (including reimbursement of expenses
      incurred) arising under the Securities Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaf353bfd808a407d84bbd56a64a637b8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exemption from Registration Claimed</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z76dfc9998fdb42e1beb8297c870f7fff" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exhibits</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1a7588b64bf4487d8091bbd23d08c51f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15.36%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div style="font-weight: bold;">Exhibit No.</div>
            </div>
          </td>
          <td style="width: 84.64%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div style="font-weight: bold;">Description</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div style="color: #000000;"><a href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121009490/nt10015006x18_ex3-1.htm">4.1</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Amended and Restated Certificate of Incorporation of Gain Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed March 22, 2021)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div style="color: #000000;"><a href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121009490/nt10015006x18_ex3-2.htm">4.2</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Amended and Restated Bylaws of Gain Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed March 22, 2021)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div style="color: #000000;"><a href="https://www.sec.gov/Archives/edgar/data/1819411/000114036121007922/nt10015006x9_ex10-1.htm">4.3</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.2 of the Registration Statement on Form S-1 of the Registrant (File No. 333-253303) filed on March 15, 2021).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div><a href="nt10015006x19_ex5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Opinion of Skadden, Arps, Slate, Meagher &amp; Flom LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div><a href="nt10015006x19_ex23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Consent of Ernst &amp; Young AG.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div><a href="nt10015006x19_ex5-1.htm">23.2*</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Consent of Skadden, Arps, Slate, Meagher &amp; Flom LLP (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15.36%; vertical-align: top;">
            <div><a href="#SIG">24.1*</a></div>
          </td>
          <td style="width: 84.64%; vertical-align: top;">
            <div style="color: #000000;">Power of Attorney (included in signature page to Registration Statement).</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;" align="left" noshade="noshade"></div>
    <div>*Filed herewith</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf7a6d6370be4e198edce7decb563dc1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">Item 9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Undertakings</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The undersigned Registrant, GAIN THERAPEUTICS, INC. undertakes:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7cbc5fd3bd9b48c2b5f6ac4c2751eee7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc68a0c22853a44e38887da3553ea20af" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top;">
            <div>to include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e8ccb23e53f4d73aa2529f3c826e68d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
              in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
              and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
              more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02ae63c3828743adab1e1e04916b2cca" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><u>provided</u>, <u>however</u>, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or
      furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement; and</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfd6380740dee4445b8a0507a24241c37" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
              securities at that time shall be deemed to be the initial bona fide offering thereof; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z319d6b61015845a8945432771070e2e4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div>to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Sections 13(a) or 15(d) of the Exchange Act (and, where
      applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating
      to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the
      Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
      controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
      such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;"><a name="SIG"><!--Anchor--></a>SIGNATURES</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
      registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, State of Maryland, on April 6, 2021.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7a829d9d0ea842bab2b964442c686eb6" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div>GAIN THERAPEUTICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div>By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Eric Richman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>Name: Eric Richman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>Title: Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Each person whose signature appears below constitutes and appoints Eric Richman and Salvatore Calabrese, and each of them, as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to
      do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, and any rules, regulations and requirements of
      the Securities and Exchange Commission thereunder, in connection with the registration of ordinary shares of the registrant under this registration statement, including, without limitation, the power and authority to sign the name of each of the
      undersigned in the capacities indicated below to this registration statement, to any and all amendments or supplements to this registration statement and to any and all instruments or documents filed as part of or in connection with this registration
      statement or any and all amendments thereto; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities set forth on the dates&#160; indicated.</div>
    <div style="text-indent: 36pt;"> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze617459eb8474e1393e2a382cbf86536" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33%; vertical-align: bottom;">
            <div style="color: #000000; font-weight: bold;">Signatures</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Title</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: bottom;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Eric Richman</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Chief Executive Officer and Director</div>
            <div style="color: #000000;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: top;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Eric Richman</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Salvatore Calabrese</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Chief Financial Officer</div>
            <div style="color: #000000;">(Principal Financial Officer and Accounting Officer)</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: top;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Salvatore Calabrese</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Khalid Islam</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Founder and Chairman</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Khalid Islam</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: middle;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Dov Goldstein</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Dov Goldstein</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: middle;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Hans Peter Hasler</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Hans Peter Hasler</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: middle;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Gwen Melincoff</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Gwen Melincoff</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Claude Nicaise</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Claude Nicaise</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: middle;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">/s/ Jeffrey Riley</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: top;">
            <div style="color: #000000;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: middle;">
            <div style="color: #000000;">April 6, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Jeffrey Riley</div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 32%; vertical-align: middle;">&#160;</td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "nt10015006x19_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 60850}]
{"company-data": {"conformed-name": "Gain Therapeutics, Inc.", "cik": "0001819411", "assigned-sic": "2834", "irs-number": "851726310", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-255061", "film-number": "21809285"}, "business-address": {"street1": "4800 HAMPDEN LANE", "street2": "SUITE 200", "city": "BETHESDA", "state": "MD", "zip": "20814", "phone": "(301) 500-1556"}, "mail-address": {"street1": "4800 HAMPDEN LANE", "street2": "SUITE 200", "city": "BETHESDA", "state": "MD", "zip": "20814"}}
As filed with the Securities and Exchange Commission on April 6, 2021
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
      20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
GAIN
      THERAPEUTICS, INC.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation or organization)
85-1726310
(I.R.S. Employer Identification No.)
4800 Hampden Lane, Suite 200
Bethesda, Maryland 20814
(Address of principal executive offices)
Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan
(Full Title of the Plan)
Eric I. Richman
Chief Executive Officer
Gain Therapeutics, Inc.
4800 Hampden Lane, Suite 200
Bethesda, MD 20814
(301) 500-1556
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copies of communications to:
Andrea L. Nicol
á
s, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
One Manhattan West
New York, New York 10001
Tel: +1 (212) 735-3000
Fax: +1 (212) 735-2000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. ◻
CALCULATION OF REGISTRATION FEE
Title of securities to be registered
Amount to be
registered (1)
Proposed
maximum offering
price per share
Proposed maximum
aggregate offering price
Amount of
registration fee
Common Stock, par value $0.0001 per share
1,153,827(2)
$14.96(3)
$17,261,251.92
$1,883.20
Common Stock, par value $0.0001 per share
517,902(4)
$3.37(5)
$1,745,329.74
$190.42
Total
1,671,729
$19,006,581.66
$2,073.62
(1)
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "
Securities Act
"), this Registration
                Statement shall also cover any additional shares of  common stock, par value $0.0001 per share ("
Common Stock
") of Gain Therapeutics, Inc. (the "
Company
") that become issuable under the Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan (the "
2020 Incentive Plan
") by reason of any future stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration by the Company that increases the number of outstanding shares of Common
                Stock.
(2)
Represents 1,153,827 shares of Common Stock reserved for issuance under the 2020 Incentive Plan.
(3)
Estimated in accordance with Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee based on a per share price of $14.96, the average of the high and low price of the common stock on
              April 1, 2021, as reported on the NASDAQ Global Market.
(4)
Represents 517,902 shares of Common Stock reserved for issuance upon the exercise of previously granted stock options that remain outstanding under the 2020 Incentive Plan.
(5)
For purposes of computing the registration fee only. Pursuant to Rule 457(h) of the Securities Act, the Proposed Maximum Offering Price Per Share is based upon the weighted-average exercise price of previously
              granted stock options that remain outstanding under the 2020 Incentive Plan.
PART I
INFORMATION REQUIRED IN THE PROSPECTUS
Item 1.
Plan Information*
Item 2.
Registrant Information and Employee Plan Annual Information*
*
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the "
Registration Statement
") in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "
Securities Act
") and the
        introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule
        428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference
The following documents filed by the Registrant are incorporated herein by reference:
(i)
the Registrant's final prospectus filed on March 22, 2021 pursuant to Rule 424(b)(4) under the Securities Act in connection with the Registrant's Registration Statement on Form S-1 (File No. 333-253303); and
(ii)
the description of the Registrant's Common Stock contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-40237) filed with the Commission on March 17, 2021.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01
      of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities
      offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any
      statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any
      subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part
      of this Registration Statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel
Not applicable.
Item 6.
Indemnification of Directors and Officers
Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the
      corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good
      faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payment of dividends or unlawful stock purchases or redemptions, or (iv) for any transaction from which the director derived an improper personal benefit.
      Our amended and restated certificate of incorporation contain such a provision.
Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys'
      fees), judgments, fines, and amounts paid in settlement in connection with specified actions, suits, or proceedings, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the corporation—a "derivative
      action"), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct
      was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys' fees) incurred in connection with defense or settlement of such action, and the statute
      requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. Our amended and restated certificate of incorporation and amended and restated bylaws contain such a
      provision.
We have in effect a directors and officers liability insurance policy indemnifying our directors and officers for certain liabilities incurred by them, including liabilities under the Securities Act and
      the Exchange Act. We pay the entire premium of this policy.
We entered into indemnification agreements with each of our directors and officers that provide the maximum indemnity allowed to directors and officers by Section 145 of the Delaware General Corporation
      Law and which allow for certain additional procedural protections.
These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities (including reimbursement of expenses
      incurred) arising under the Securities Act.
Item 7.
Exemption from Registration Claimed
Not applicable.
Item 8.
Exhibits
Exhibit No.
Description
4.1
Amended and Restated Certificate of Incorporation of Gain Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed March 22, 2021)
4.2
Amended and Restated Bylaws of Gain Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed March 22, 2021)
4.3
Gain Therapeutics, Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.2 of the Registration Statement on Form S-1 of the Registrant (File No. 333-253303) filed on March 15, 2021).
5.1*
Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.
23.1*
Consent of Ernst & Young AG.
23.2*
Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).
24.1*
Power of Attorney (included in signature page to Registration Statement).
*Filed herewith
Item 9.
Undertakings
The undersigned Registrant, GAIN THERAPEUTICS, INC. undertakes:
(1)
to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
              in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
              and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
              more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.
provided
,
however
, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or
      furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement; and
(2)
that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
              securities at that time shall be deemed to be the initial bona fide offering thereof; and
(3)
to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Sections 13(a) or 15(d) of the Exchange Act (and, where
      applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating
      to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the
      Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
      controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
      such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
      registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, State of Maryland, on April 6, 2021.
GAIN THERAPEUTICS, INC.
By:
/s/ Eric Richman
Name: Eric Richman
Title: Chief Executive Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Eric Richman and Salvatore Calabrese, and each of them, as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to
      do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, and any rules, regulations and requirements of
      the Securities and Exchange Commission thereunder, in connection with the registration of ordinary shares of the registrant under this registration statement, including, without limitation, the power and authority to sign the name of each of the
      undersigned in the capacities indicated below to this registration statement, to any and all amendments or supplements to this registration statement and to any and all instruments or documents filed as part of or in connection with this registration
      statement or any and all amendments thereto; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities set forth on the dates  indicated.
Signatures
Title
Date
/s/ Eric Richman
Chief Executive Officer and Director
(Principal Executive Officer)
April 6, 2021
Eric Richman
/s/ Salvatore Calabrese
Chief Financial Officer
(Principal Financial Officer and Accounting Officer)
April 6, 2021
Salvatore Calabrese
/s/ Khalid Islam
Founder and Chairman
April 6, 2021
Khalid Islam
/s/ Dov Goldstein
Director
April 6, 2021
Dov Goldstein
/s/ Hans Peter Hasler
Director
April 6, 2021
Hans Peter Hasler
/s/ Gwen Melincoff
Director
April 6, 2021
Gwen Melincoff
/s/ Claude Nicaise
Director
April 6, 2021
Claude Nicaise
/s/ Jeffrey Riley
Director
April 6, 2021
Jeffrey Riley